The short version of post-marketing surveillance fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-07-21. Anything still debated is marked as such rather than presented as settled.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular mass | About 1024.2 g/mol | Monoisotopic value for the free base |
| Appearance | White to off-white lyophilized powder | Visual inspection is not an identity test |
| Solubility | Soluble in water and polar organic solvents | Dissolution depends on salt form and pH |
| Typical storage | -20 °C, dry, protected from light | Powder is more stable than prepared solutions |
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
=== Bombing of Laos === In February 1970, several senators led by J. William Fulbright and Stu Symington first learned that the United States had been bombing Laos since December 1964, which led to complaints in Congress about the "secret war" in Laos. Nixon reluctantly decided to admit to the "secret war", and directed Kissinger to issue the necessary statement to the media. Kissinger's statement admitted to the bombing of Laos, but also claimed: "No American stationed in Laos has ever been killed in ground combat operations". Two days later, it emerged that a U.S. Army captain had been killed while fighting in Laos and subsequently the Pentagon admitted that in the period February 1969-February 1970 a total of 27 Americans had been killed in Laos. Kissinger claimed that he had not lied, maintaining that all Americans killed in Laos were in "hot pursuit" when chasing the enemy from South Vietnam into Laos, but this argument made no impression. Nixon stated: "No one cares about B-52 strikes in Laos, but people worry about our boys out there". Nixon refused to see Kissinger for the next week, saying that his statement about Laos had caused him to drop 11 points in the public opinion polls.
In the 1700s, ivory dentures were developed from walrus, elephant or hippopotamus tusks. Alexis Duchateu crafted the first porcelain dentures in 1770. These were prone to cracking and appeared too white to be natural teeth. Duchateus was a pharmacist, since Denturist, as an occupation was yet to be established. In the 1800s, the incidence of dental decay and tooth loss began to increase rapidly. The industrialisation period meant the consumption of sugar among British citizens increased by 500 percent. A need for an alternative form of dentures was needed. In 1815, the Battle of Waterloo gave rise to the highly demanded "Waterloo teeth". These were dentures crafted primarily from the teeth of dead soldiers seated in a base of animal ivory. Waterloo dentures gave the appearance of natural teeth and were not as prone to breakage as porcelain dentures. In 1820, Claudius Ash was given the task of crafting a new and improved form of dentures. Ash was a silversmith and goldsmith. He constructed porcelain on 18-karat gold plates. The springs that held the dentures together were also made of gold. Dentures that were previously made from natural teeth or porcelain were both aesthetically and functionally inferior in comparison to Ash's design. In the 1850s, Ash and his company developed Vulcanite (hardened rubber that seated porcelain teeth). His company was the leading supplier of this form of dentures in Europe. Charles Goodyear was awarded the patent for Vulcanite-based dentures in 1851. Dentures, at the time, were primarily focused on aesthetics.
Salvia divinorum is native to the Sierra Mazateca in Oaxaca, Mexico, where it is still used by the Mazatec, primarily to facilitate shamanic visions in the context of curing or divination. S. divinorum is one of several plant species with hallucinogenic properties that are ritually used by Mazatec shamans. In their rituals, the shamans use only freshly harvested S. divinorum leaves. They see the plant as an incarnation of the Virgin Mary, and begin the ritual with an invocation to Mary, Saint Peter, the Holy Trinity, and other saints. Ritual use traditionally involves being in a quiet place after ingestion of the leaf—the Maztec shamans say that "La Maria (S. divinorum) speaks with a quiet voice." It is also used in smaller amounts, as a diuretic, and to treat ailments including diarrhea, anemia, headaches, rheumatism, and a semi-magical disease known as panzón de borrego, or a swollen belly (literally, "lamb belly"). The history of the plant is not well known, and there has been no definitive answer to the question of its origin. Speculation includes Salvia divinorum being a wild plant native to the area; a cultigen of the Mazatecs; or a cultigen introduced by another Indigenous group. Botanists have also not been able to determine whether it is a hybrid or a cultigen.
Sources: en.wikipedia.org
Electroencephalography – may have a characteristic generalized periodic sharp wave pattern. Periodic sharp wave complexes develop in half of the people with sporadic CJD, particularly in the later stages. Cerebrospinal fluid (CSF) analysis for elevated levels of 14-3-3 protein and tau protein could be supportive in the diagnosis of sCJD. The two proteins are released into the CSF by damaged nerve cells. Increased levels of tau or 14-3-3 proteins are seen in 90% of prion diseases. The markers have a specificity of 95% in clinical symptoms suggestive of CJD, but specificity is 70% in other, less characteristic cases. 14-3-3 and tau proteins may also be elevated in the CSF after ischemic strokes, inflammatory brain diseases, or seizures. The protein markers are also less specific in early CJD, genetic CJD or the bovine variant. However, a positive result should not be regarded as sufficient for the diagnosis. The real-time quaking-induced conversion (RT-QuIC) assay, which amplifies misfolded PrPSc, now plays a central role in CJD diagnosis. Second-generation RT-QuIC on cerebrospinal fluid has sensitivity in the 90–97% range and ~100% specificity in sporadic CJD, far superior to earlier CSF tests. A positive RT-QuIC (on CSF or other tissues) is now included as a criterion for probable CJD in many national surveillance centers. Studies have shown RT-QuIC can also be done on olfactory mucosa swabs obtained via nasal brushing and on skin biopsies, with high diagnostic accuracy (reported sensitivities ~90–100%).
This layer acts as a nucleation site during the next step, where a process of electroless deposition layers a coating of gold on the nanotubes to form metal-insulator-metal trilayer coaxial nanocables. Peptide nanotubes are able to produce nanowires of uniform size, and this is particularly useful in the nano-electric applications as electrical and magnetic properties are sensitive to size. Nanotubes' exceptional mechanical strength and stability makes them excellent materials for application in this area. Nanotubes have also been used in developing electrochemical biosensing platforms and have proved to have great potential. Dipeptide nanotubes deposited on graphite electrodes improved electrode sensitivity; thiol-modified nanotubes deposited on gold with a coating of enzymes improved sensitivity and reproducibility for the detection of glucose and ethanol, as well as a shortened detection time, large current density, and improved stability. Nanotubes have also been successfully coated with proteins, nanocrystals, and metalloporphyrin through hydrogen bonding, and these coated tubes have great potential as chemical sensors. Designed peptides with a known structure that would self-assemble into a regular growth template would enable the self-assembly of nanoscale electronic circuits and devices. However, one issue that has yet to be resolved is the ability to control the positioning of the nanostructures. This positioning relative to substrates, to each other, and to other functional components is crucial.
In the absence of catalysts, proteins are slow to hydrolyze. The breakdown of proteins to small peptides and amino acids (proteolysis) is a step in digestion; these breakdown products are then absorbed in the small intestine. The hydrolysis of proteins relies on enzymes called proteases or peptidases. Proteases, which are themselves proteins, come in several types according to the particular peptide bonds that they cleave as well as their tendency to cleave peptide bonds at the terminus of a protein (exopeptidases) vs peptide bonds at the interior of the protein (endopeptidases). Pepsin is an endopeptidase in the stomach. Subsequent to the stomach, the pancreas secretes other proteases to complete the hydrolysis, these include trypsin and chymotrypsin. Protein hydrolysis is employed commercially as a means of producing amino acids from bulk sources of protein, such as blood meal, feathers, keratin. Such materials are treated with hot hydrochloric acid, which effects the hydrolysis of the peptide bonds.
Bethlem myopathy may be diagnosed based on clinical examinations and laboratory tests may be recommended. Genetic testing for known pathological variants is preferred. In the case of a VUS, testing of dermal fibroblast culture is used for an accurate diagnosis. Bethlem myopathy 1 is a rare disease, affecting about 1 in 200,000 people. Bethlem myopathy 2 is an ultra-rare disease, affecting less than 1 in 1,000,000 people. The condition was described by J. Bethlem and G. K. van Wijngaarden in 1976.
Sources: en.wikipedia.org
Dry powder is usually held frozen, shielded from light, and kept away from moisture. Desiccant packaging limits hydrolysis during storage. Solutions are typically aliquoted and frozen once, because repeated thawing shortens useful life.
Mass spectrometry establishes molecular mass, and reversed-phase chromatography reports purity. Peptide mapping or amino acid analysis supports sequence-level confirmation. No single technique covers all failure modes, so laboratories combine results.
Common entries include appearance, purity by chromatographic area, measured mass, and sometimes residual solvents or counter-ion content. Methods and instrument conditions are not always described. The document reflects the supplier's own testing unless an independent laboratory is named.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.